GSR Commits $100M to Hare Onchain Credit Vaults 
Rapidus Seeks Chip Customers as Japan Pushes 2nm Semiconductor Revival 
Kazakhstan and Tether Explore Tenge Stablecoin and RWA Tokenization 
Gate Launches Gate Money as Crypto Super App Race Heats Up 
Paramount Skydance Completes $110 Billion Warner Bros Discovery Deal 
Levi Strauss Beats Q3 Profit Estimates, Raises 2026 Outlook 
Europol Warns Bitcoin Wallets Face Quantum Computing Risk 
Bitmine to Stop Ethereum Buying After Reaching 5% ETH Supply 
Iceland 4x4 Rental Guide: When Do You Really Need Four-Wheel Drive? 
Zcash Privacy Demand Rises as AI Exposes Bitcoin Transactions 
Broadcom, Oracle and SpaceX Seek Billions in Private Debt for AI Expansion 
Micron Shares Rise 4% Despite Taiwan Strike Risk 
Litecoin Marks 15 Years as Grayscale Backs LTC ETF Push 
Constellation Brands Beats Q2 Estimates, Buys SpikedAde 
Circle Stock Falls 4% as Crypto Selloff Overshadows SAP Pay Expansion 
HSBC Plans Deep UK Wealth Job Cuts in AI Push 
Intel Reaffirms Role in Elon Musk’s Terafab Chip Project 
Add as a preferred source on Google
A US district court upheld the validity of Novartis' patent for its top-selling multiple sclerosis (MS) drug Gilenya, rejecting a lawsuit from generic drug maker HEC.
Gilenya is the Swiss drugmaker's No. 2 revenue generator at $738 million in the second quarter.
HEC had sought approval to make a generic copy of Gilenya before the expiration of Novartis' patent with the US Food and Drug Administration (FDA).
The Swiss drugmaker said it continued the injunction against the marketing and sale of Gilenya and other generics granted to it in June 2019.
The FDA approved three generic versions of the Novartis MS treatment in December.
Novartis had settlement agreements with other manufacturers to allow them to launch generic versions of Gilenya before the patent expires in 2027.
